Tofacitinib Ointment For Chronic Plaque Psoriasis

• Status: Completed
• Trial end date: 2014-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The study is beng done to test if tofacitinib ointment is safe and effective for people with plaque psoriasis. Two dose strengths of tofacitinib ointment (20 mg/g and 10 mg/g) applied once or twice daily are being tested. The safety and effectiveness of tofacitinib ointment used for 12 weeks will be compared to the safety and effectiveness of placebo ointment (vehicle) used for 12 weeks.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Tofacitinib

Criteria

Inclusion Criteria:

• Have mild, moderate or severe plaque psoriasis (psoriasis vulgaris) for at least 6 months prior to Baseline

• At Baseline, have plaque psoriasis covering 2% to 20% of total body surface area (BSA) on the trunk and limbs (excluding palms, soles, and nails)

• If received certain treatments, should be off treatment for a minimum period of time (washout)

Exclusion Criteria:

• Currently have non-plaque forms of psoriasis or drug-induced psoriasis

• Require treatment with or cannot stop medication(s) prohibited during the study

• Have certain laboratory abnormalities at Baseline

• Current or history of certain infections

• Females who are pregnant, breastfeeding, or are of childbearing potential not using highly effective contraception